Andrew Chen founded LATITUDE Pharmaceuticals Inc. in 2003 to address the increasingly difficult formulation challenges facing biotech and pharmaceutical companies. With over 20 years of formulation experience covering small molecule, peptide, protein, nucleic acid, and virus-based pharmaceuticals, Andrew’s deep experience enables LATITUDE to rapidly pinpoint key issues with difficult compounds and rapidly develop toxicology and commercial formulations for its clients.